Big Data & Analytics for Pharma

Gain greater insight through big data & analytics

June 12 & 13, 2013Philadelphia, PA

Speakers

Companies Presenting

• Director, Analytics, Merck• Chief Executive Office, Aquavit Pharma• Senior Director, Analytics, Horizon Pharma• Director, Biomed Informatics, AstraZeneca • Chief Technology Officer, Wyle Science• Director, Bentley University • Senior Manager, Analytics, Astellas Pharma• Director, Lean Six Sigma, Merck• Professor, St Joseph’s• Head of R&D Information, AstraZeneca

• Director, Pharma Policy & Strategy, Atena• Director, HR, Quest Diagnostics• Manager, Business Intelligence, Abbvie• Manager, Analytics, Nostrum Labs• Senior, Architect, UNC• Manager, Data Mining, Janssen R&D• Director, Governance & Operations, Bristol-

Myers Squibb

1

Who Will You Meet There is no question that IE. provides the gold standard events in the industry and will connect you with decision makers within the analytics industry. You will be meeting senior level executives from major corporations and innovative small to medium size companies.

Job Title Of Attendees

President/Principal

SVP/VP

C-Level

Snr. Director/Director

Global Head/ Head

Snr. Manager/Manager

Academic (1%)

78%

1000+ Employees300-999 Employees50-299 EmployeesLess than 49 Employees

Company Size Of Attendees

8%

11%

25%56% 81%Attendees are

companies with at least 300

employees

3%

21%

12%

42%

13%

8%

Attendees are at Director level or above

2

Past Delegates Include• Senior Director, Starbucks

• VP, Head of Analytics & Information Services - Visa

• Vice President - Google

• Head of Business Analytics, eBay

• Director, Analytics - Coca-Cola

• Director, Analytics & Value Optimisation - RBS

F TI L

The Advanced Analytics for Pharma and Biotech Summit brings together thought-leaders from the industry for an event acclaimed for its interactive sessions and high-level speakers.. As many organisations are now gathering more data on customers and clients than ever before, they are able to achieve 360 degree view on the market and view patterns in their data. This presents both a challenge and opportunity as organisations must gain actionable results in order to succeed. Bringing together the decision makers and leaders from within the industry, this event will focus on the challenges specific to the Healthcare industry

surrounding data analytics, insight and data visualisation, as well as the benefits of using analytics and analysis in a rapidly evolving and challenging industry. Illustrated with industry case studies as well as informative panels and breakout sessions, this summit promises to be the must attend event for data scientists in the Healthcare industry

Jianing Di, PhD, is a manager of modeling and data mining at Janssen R&D, the pharmaceutical section of Johnson and Johnson. Since he joined Janssen R&D in 2008, he has been working on clinical drug development in different therapeutical areas, with a current focus in the Alzheimer’s disease. At his current role, he is leading the data mining activities across multiple datasets, aiming at improving the efficiency of clinical studies through patient population enrichment and endpoint selection.

Finding Right Patients for our Next Clinical Trial.

Finding the right patient population is one of the most essential steps to ensure a successful clinical study. For a clinical trial, patient identification may be applied at any time from study enrollment to data analysis. A set of enrichment strategies via adaptive design, continuous monitoring, and data mining can be applied to promote accurate assessment of the drug effect. In this talk, we will consider some common issues in patient recruitment and discuss some typical statistical approaches for patient population enrichment. Potential issues of these methodologies will also be discussed.

3

Speakers Information

Speakers Information

Jianing Di,Manager, Modeling & Data Mining.Janssen

Mihaela Ugarcovici is Senior Manager, Marketing Analytics at Astellas Pharma US Inc., a US affiliate of Tokyo-based Astellas Pharma Inc.  In her role at Astellas, Mihaela is providing actionable insights to the marketing and sales leadership teams, by developing advanced models and innovative data mining techniques to measure the effectiveness of key selling and marketing activities, assess key business impact drivers, as well as optimize the allocation of promotional dollars across marketing tactics.  Prior to joining Astellas in 2011, Mihaela has spent 10 years in various marketing and sales analytics roles at Lundbeck, Novartis, and ZS Associates.

Promotional & Economic Dynamics in Pharma

Traditional marketing mix models are utilized to support short term sales and marketing tactical planning.  They quantify the impact of past tactics used to promote a brand (or portfolio), and inform future decisions on continuing, improving, or stopping promotional activities.  However, these models often under-state long-term branding and external factors’ influence.  A macro econometric model addresses these long-term strategy decisions and market events.  In addition to sales and marketing activities, it takes into consideration several economic factors over longer periods of time, to identify drivers of market trends and adapt the strategy based on these drivers (to maximize both short-term and long term returns).

Mihaela Ugarcovici,Senior Manager, Marketing AnalyticsAstella Pharma

Speaker Information

Dr. Ledley is a pioneer the translation of molecular and genomic science in medicine and industry. He is Director of the Center for Integration of Science and Industry as well as Professor of Natural & Applied Sciences and Management at Bentley University in Waltham, MA.  Dr. Ledley served previously on the faculties of the Howard Hughes Medical Institute and Baylor College of Medicine, was founder and VP R&D of GeneMedicine, Inc., and was the founding President & CEO of Variagenics Inc.  He has authored >150 papers and 10 US patents on molecular biology, gene therapy, drug development, and personalized medicine.

Fred Ledley,Director, Center of Integration of Science & IndustryBentley University

Data Analytics & Technology Life Cycles in Biopharmaceutical Development

The maturation of technology through a characteristic life cycle has an important influence on product success. Data analytics can be used to model the progression of knowledge and technological capabilities of therapeutic targets and classes of therapeutic entities through their life cycles.  Our work describes how this progress correlates with successful product development and sustainable business strategies in the biopharmaceutical industry.  This data driven and theory-based analysis of scientific and technological advances can inform investments, business strategy, portfolio optimization, project management, and clinical development.

Patrick J. Howie joined Merck at the end of 2012 to lead the Data Integration and Analytics team.  His previous roles include the SVP of Analytics at Physicians Interactive and the SVP of Product Development at TargetRx.  Patrick is the author of The Evolution of Revolutions (Prometheus Books)  as well as numerous publications in both academic and trade press.

Making Big Data Small - Bridging the Gap Between IT & Marketing

Big Data is both exciting and mystifying to marketers – they are excited by the possibility of uncovering new insights into customers but are mystified by the inability to experience the data and the IT terminology – NLP, terabytes, 4Vs – used to discuss how to process all of this data.  This talk will describe how we are getting Big Data into the hands of Marketing and the broader market research group in a way that they can gain direct experience and derive novel insights.

Patrick HowieDirector, AnalyticsMerck

Lisa Beerman has been with Quest Diagnostics for over twenty-five years, during which time she has held over a dozen positions in five different functional areas working in Operations, Project Management, Sales and Marketing, and the past ten years as a Director of Human Resources for the South Region. Lisa is both a certified Senior Professional of Human ResourceLisa Beerman has been with Quest Diagnostics for over twenty-five years,

Human Sigma: Driving Engagement for Business Results

A data driven company always seeks the facts, data and processes. However, our “humans”, and their behaviors, whether employees or customers, don’t often fit neatly into an Excel spreadsheet and it is difficult to predict which actions will have which exact impacts.  Engagement studies by Gallop involving Human Sigma, guided us in taking clear actions related to these key principles resulting in a growth turnaround for our multi-million dollar business. From organizational structural changes, to moving the touch points for our customers, to transformational development of our leadership, this case study will outline ways that any organization can capitalize on its “Human Sigma” potential.

Lisa BeermanDirector, Human ResourcesQuest Diagnostics

Speaker Information

A certified Master Black Belt and Change Agent, Barney has over 12 years of experience executing process improvement strategies for shared service organizations. He currently manages realization of the analytics project portfolio and performance optimization activities for Merck’s Shared Business Services (SBS) organization. In this role, he manages our analytics return on investment, designs and facilitates Rapid Results workshops, and advances continuous improvement skills in shared services.  Since the formation of SBS in 2007, Barney has led the global Lean Six Sigma implementation.  Prior to joining Merck, Barney managed process improvement strategies

Barnaby FountainDirector, Lean Six SigmaMerck & Co.

in Honeywell's Global Business Services organization as a Black Belt and IT Program Manager.

Business Insight: Using Data & Predictive Analytics to Deliver Business Value

Merck is realizing the value of large data analytics projects and has effectively been using data in SAP and other sources to gain insight into the performance of their end to end business processes. In 2012, the analytics project portfolio enabled teams to deliver over $100M in business value.  The success of the data analytics program is enabled by Merck’s data management controls. Without high quality data (customer, supplier, finance, etc.), the analytics would be ineffective.

Dr. Thani Jambulingam is a highly respected associate professor in our department.  He brings his award winning research into the classroom and demonstrates how pharmaceutical supply chains are instrumental to a company's success.  Students are both challenged and engaged by this cutting edge material.

Outside of the classroom, Dr. Jambulingam is a reviewer for pharmacy journals (Annals of Pharmacotherapy, American Journal of Managed Care Pharmacy), AdHoc

reviewer for marketing and management journals (Journal of Marketing, Journal of Business Venturing).

Big Data: Can it Create Value & Competitive Advantage for Pharma?

With exploding new source of data and the advent of new technologies can pharma create value and competitive advantage to successfully innovate, compete, and meet customer needs in the future?

Thani JambulingamProfessor, Department of PharmaSaint Joseph’s University

Dr. Labkoff is a visionary medical leader with a track record of developing cutting edge strategies towards new healthcare delivery models. He has demonstrated success in the convergence of medicine, life sciences and policy across disparate organizations including government, nongovernment organizations (NGOs), health plans and academic institutions.

Dig Data to Transform Pharma R&D: Asking the Right Questions

How to ensure that you are asking the right questions of Big Data and ensure the human element isn’t the weak link in data interrogation. Identifying the right patients for the right drug in the make or break Phase II trial stage using Big Data. Best practices for distilling mountains of imaging results, disease progression readings and genotypic traits to find your target participants

Steven LabkoffHead of Strategic Programs, R&D InformationAstraZeneca

Speaker Information

Chris brings more than 15 years of management and marketing operations expertise to his role as Director of Governance and Operations at Bristol-Myers Squibb. He currently oversees medical information customer center operations and business intelligence reporting in regions as diverse as the Americas, Europe, Asia, Middle East and Africa. He has been widely referenced by trade and general publications such as Credit Card Management, Internet Retailer, USA Today, Delaware News Journal and the New York Times regarding his insight into the marketing and financial service industries.

Christopher KeenanDirector, Governance & OperationsBristol-Myers Squibb

Performance Management: Leveraging Big Data for Innovation

This session explores a typical transformational journey from legacy reporting to a unified data environment focused on insights rather than solely metrics. This includes a discussion on architectural framework and the use of data visualization to guide users from static reporting to self guided analytics.

Edmund Pezalla, M.D., MPH, is National Medical Director for Pharmaceutical Policy and Strategy. He is responsible directly to the Chief Medical Officer for the and integration of pharmacy policy and activities into Aetna’s overall strategy and operations. Dr. Pezalla also serves as the lead clinical spokesperson for Aetna in pharmacy related issues and represents Aetna on industry work groups and conferences. 

Analytics with Pharmaceutical Policy & Strategy

This presentation will look into how data informs Policy & Strategy allowing for development, implementation and evaluation. How do we incorporate clinical data collection alongside claims/cost data and create an innovative environment both within our company and the provider groups we work with.

Edmund PezallaNational Medical Director, Pharmacy Policy & StrategyAetna

Dr. Ledley is a pioneer the translation of molecular and genomic science in medicine and industry. He is Director of the Center for Integration of Science and Industry as well as Professor of Natural & Applied Sciences and Management at Bentley University in Waltham, MA.  Dr. Ledley served previously on the faculties of the Howard Hughes Medical Institute and Baylor College of Medicine, was founder and VP R&D of GeneMedicine, Inc., and was the founding President & CEO of Variagenics Inc.  He has authored >150 papers and 10 US patents on molecular biology, gene therapy, drug development, and personalized medicine.

Leveraging the Research Enterprise’s Big Data Efforts

The national research enterprise is doing cutting edge work involving Big Data. This session presents an overview of selected Big Data efforts at the University of North Carolina at Chapel Hill as part of larger national efforts involving the National Institutes of Health, the National Science Foundation, the National Consortium for Data Science, and others.

Michael ShoffnerSenior Research Software ArchitectUniversity of North Carolina

Speaker Information

Patrick Hayes has over 30 years experience in across strategy, planning and business operations with a record of effectively transforming marketing, channel management and sales, product management and customer service operations. During his consulting career his projects have focused on Digital Strategy, Mobile, Growth and Innovation, Business Transformation, Customer, Product Marketing, Sales and Service Strategies, and Technology Integration.

.

Patrick HayesManaging DirectorGaligeo

Mobility: How Location Intelligence is Moving Outside the Office to Become an Enterprise Productivity Tool.

The benefits of Location intelligence has moved beyond the traditional BI users or Analysts. Portable devices and 4G bandwidth puts Location Intelligence in the hands of new groups of users. Now Location Intelligence capabilities, integrated with BI dashboards and CRM/Marketing analytic tools help field marketing localize campaigns and sales teams to better manage their territories and accounts, with improved productivity through new ways to visualize data and information. New tablet devices combined with 4G speeds significantly enhance and improve access to rich data visualization delivered by location intelligence functionality

Mr. Bush currently is the Senior Director for Commercial Analytics at Horizon Pharma where he joined at their IPO in 2011.  Mr. Bush has over fifteen years of experience in various commercial leadership positions in specialty pharmaceutical, pharmaceutical and consulting companies.  He most recently led forecasting and marketing teams for Astellas and Abbott (now AbbVie) where his positions spanned both domestic and international and Primary Care through Specialty/Hospital product portfolios.  

Delivering Commercial Analytics in an Emerging Pharma Atmosphere.

Today’s pharmaceutical landscape includes a significant number of smaller, emerging pharmaceutical and biotechnology companies. Seeking to maximize their assets, more of these companies are choosing to commercialize independently or concurrently with partners. Marketing and Sales organizations rely on their analytical groups to provide timely, focused insights to drive the critical decisions leading to growth.

Bill BushSenior Director, Commercial AnalyticsHorizon Pharma

Zhaohui (John) Cai, MD, PhD, is a Biomedical Informatics Director supporting Payer and Real World Evidence (RWE) in AstraZeneca.  He received his MD from China Medical University, PhD from Albany Medical College, and Medical Informatics Fellowship training from Harvard Medical School. John leads a Medical Informatics group providing RWE study services to early and late stage drug projects, as well as supporting other strategic programs in AstraZeneca, including Personalized Health Care, Clinical Trial Design and Interpretation, and Predictive Safety.

Predictive Analytics for Personalized Healthcare

Comparative Effectiveness Research (CER) is promising to fill the evidence gaps for decision making by healthcare stakeholeders, including providers, patients, payers, and policy makers. However, it seems risky to implement policies or guideline based on a general “drug A is better than drug B for disease X” kind of comparative effectiveness, when facing individual patients in real-world healthcare. The decision makers  need to know to what patient subgroup, what disease stage, and what treatment pathway, a comparative effectiveness evidence is applicable.

Michael ShoffnerSenior Research Software ArchitectUniversity of North Carolina

Speaker Information

Omar works at Abbvie in Mexico city and is currently the manager for Business Intelligence the main objective of the position is to develop a knowledge base with information of sales force effectiveness, primary and secondary market research and stakeholders insights.

Omar has a 13 years of experience in pharmaceutical companies such as Sanofi, Wyeth and Abbott, he is very passionate about how can the data visualization can help to the organization to understand their data.

.

Patrick HayesManaging DirectorGaligeo

Delivering the Right Message Through Data Visualization Automated Analysis.

Delivering the right message through data visualization and automated analysis, the main objective of Business Intelligence is transform the data into knowledge for the organization, but in between we can miss the message due the noise in the organization and the personal perception of the people.

In order to avoid that we have a lot of tools like data visualization and algorithms for automated analysis, we are going to explore some options to deliver the message without this noise

Susan, since graduating with a Doctors in Pharmacy has since gone on the achieve a Masters in Public Health. alongside her academic achievements Susan has gained a wealth of experience within the Pharmaceutical and Healthcare industry. Since starting at Novartis as the Regional Scientific Associate Director Susan has taken on a number of different roles, now heading up the Primary Care & Established Medicines Health Economic & Outcomes Research.

Leveraging the Data Continuum to Meet Evolving Demand

Healthcare stakeholders, including patients, providers, policy makers and payers, are increasingly demanding new evidence to help drive decision making.  Novartis has realized the need for and the value of delivering this evidence and in turn, is exploring ways to integrate various non-traditional study designs into the development process. 

·

Susan MassaroHead & Business Partner, Respiratory US Health Economics & Outcomes ResearchNovartis

Harish Gosike has over 8 years of experience in the Pharmaceutical Industry in marketing, market analysis and product launch in addition to Regulatory affairs (CMC) and Research and Development. He currently drives the Research and Development group at Nostrum Laboratories focusing on Generic drug development and submissions. In his current managerial role he develop teams and provide insights on market research to choose the right generic and help formulate and file the generic ANDA in addition to the commercial products.)

Pruning the R&D Pipeline with Big Data Pharma

Targeting the right customer drives the success for every industry. The growing industry and health care needs of the pharma and biotech industry is to determine the right customer/patient. With the expiring patent cliff, emerging regulatory concerns and generic giants, NME’s and new BLs have become a challenge for the next generation therapeutics and financial outcomes. With data being collected from the past decade, the use and applications of data, technology and scientific collaborations play a vital role in increasing clinical trial efficiency and contribute to next generation R&D therapeutics. .

Harish GosikeManager, Analytics R&DNostrum Laboratories

The Information

For larger groups or special requests contact William by calling +1 415 992 7897 or email wtubbs@theiegroup.com Team discounts are applicable at the point of registration only.

Ways to Register

Silver Pass

$1195Access to all sessions &

networking event

$1095Early Bird Price(before April 5)

Diamond Pass

$1695Access to all sessions, networking events, annual subscription to IE.

membership & Strategic Analysis Report

$1495Early Bird Price(before April 5)

Gold Pass

$1495to all sessions, networking events &

annual subscription to IE. membership

$1395Early Bird Price(before April 5)

+1 425 992 7897 +1 323 446 7673 https://theinnovationenterprise.com/summits/Big-Data-for-Pharma/registration

Group Discount Offers3 Silver Passes: $3000 ($1000 per attendee)5 Silver Passes: $4500 ($900 per attendee)3 Gold Passes: $3900 ($1300 per attendee)5 Gold Passes: $6000 ($1200 per attendee)3 Diamond Passes: $4500 ($1500 per attendee)5 Diamond Passes: $7000 ($1400 per attendee)

Registration Pricing

Big Data & Analytics for Pharma SummitDate: June 12 & 13, 2013Location: Philadelphia, Pennsylvania Venue: Ritz-Carlton Philadelphia

9

F TI L

NAME OF EACH ATTENDEE

TITLE OF EACH ATTENDEE DEPARTMENT

COMPANY INDUSTRY

ADDRESS CITY

STATE/PROVINCE ZIP/POSTAL CODE COUNTRY

EMAIL OF EACH ATTENDEE BUSINESS PHONE NUMBER

1. Delegate Information...

2. Pass Types...Early Bird Pass Options until April 5 2013

Early Bird Silver: $1195 Attendees ____ Early Bird Gold: $1495 Attendees ____ Early Bird Diamond: $1695 Attendees ____

Regular Pass Options after April 5, 2013 Silver Pass: $1395 Attendees ____ Gold Pass: $1695 Attendees ____ Diamond Pass: $1895 Attendees ____

Group Discount Pass Options 3 Silver Passes $3000 ($1000 per attendee) 5 Silver Passes $4500 ($900 per attendee) 3 Gold Passes $3900 ($1300 per attendee) 5 Gold Passes $6000 ($1200 per attendee) 3 Diamond Passes $4500 ($1500 per attendee) 5 Diamond Passes $7000 ($1400 per attendee)

For larger groups or special requests contact William Tubbs by calling +1 (415) 992 7897 or email wtubbs@theiegroup.com Group passes only available when all participants register together.

Pass Descriptions:Silver Pass: Access to all sessions & networking eventsGold Pass: Access to all sessions, networking events & annual subscription to IE. membershipDiamond Pass: Access to all sessions, networking events, annual subscription to IE. membership & Strategic Analysis Report

Check (Make checks payable to The Innovation Enterprise Ltd) Invoice me

Visa Mastercard American Express Diners Club Discover

CARD NUMBER EXPIRATION DATE SECURITY NO.

CARDHOLDERS NAME CARDHOLDER’S SIGNATURE

BILLING ADDRESS -(same as above) INDUSTRY

Prices are exclusive of VAT. Places are transferable without any charge to another Summit occurring within 12 months of the original purchase. Team discounts are applicable at the point of registration only. Any cancellations within a group registration will in turn incur an increase in registration fee for the remaining group participants. Cancellations before May 08, 2013 incur an administrative charge of 50%. If you cancel your registration after May 08, 2013 you will be charged the full fee. You must notify The Innovation Enterprise in writing of a cancellation, or you will be charged the full fee. The Innovation Enterprise reserve the right to make changes to the program without notice. NB: FULL PAYMENT MUST BE RECEIVED BEFORE THE EVENT.

Registration FormBig Data & Analytics for Pharma SummitJune 12 & 13, 2013 | Philadelphia PAFor registration or more information on the program, please call William on +1 (415) 992 7897 , or fax this registration form to +1 (323) 446 7673

3. Payment Options...

Schedule

Networking Drinks 17.00 - 19.00

June 13

Session One 08.30 - 10.00

Coffee Break 10.00 - 10.30

Session Two 10.30 - 12.00

Lunch 12.00 - 13.30

Session Three 13.30 - 15.00

Coffee Break 15.00 - 15.30

Session Four 15.30 - 17.00

Day Two

June 12Day One 08.30

10.00

10.30

12.00

13.30

15.00

15.30

17.00

19.00

08.30

10.00

10.30

12.00

13.30

15.00

15.30

17.00

Session Five 08.30 - 10.00

Coffee Break 10.00 - 10.30

Session Six 10.30 - 12.00

Lunch 12.00 - 13.30

Session Seven 13.30 - 15.00

Coffee Break 15.00 - 15.30

Session Eight 15.30 - 17.00

11

Sponsors

For more information, contact us at pcurtis@theiegroup.com

Exhibitor

Exhibitor

12

Silver Sponsor

F TI L

NovemberData Science Leadership Summit November 14 & 15Chicago

Big Data Metrics SummitNovember 14 & 15Chicago

Big Data FestNovember 27London

Big Data Innovation SummitNovember 28 & 29Beijing

DecemberBig Data in FinanceSummitDecember 5 & 6New York

OctoberBig Data InnovationSummitOctober 17 & 18Beijing

Big Data & Predictive Analytics Summit October 17 & 18Dublin

Big Data InnovationSummitOctober 31 & November 1Mumbai

AprilWomen in Big Data & Tech SummitApril 11 & 12San Francisco

Big Data Innovation SummitApril 11 & 12San Francisco

Hadoop Innovation SummitApril 11 & 12San Francisco

Data Visualization SummitApril 11 & 12San Francisco

Big Data Innovation SummitApril 18 & 19Hong Kong

Big Data Innovation SummitApril 30 & May 1London

JanuaryBig Data Innovation SummitJanuary 30 & 31Las Vegas

FebruaryHadoop InnovationSummitFebruary 20 & 21San Diego

JuneBig Data Innovation Summit June13 & 14Singapore

Big Data & Analytics for PharmaJune 12 & 13Philadelphia

Big Data Innovation SummitJune 20 & 21Toronto

Big Data & Analytics in Retail June 20 & 21Chicago

MayBig Data & Analytics in Healthcare May 15 & 16Philadelphia

Big Data & Advanced Analytics in Government May 23 & 24Washington, DC

SeptemberBig Data Innovation SummitSeptember 12 & 13Boston

Data Visualization SummitSeptember 12 & 13San Francisco

Big Data Innovation SummitSeptember 19 & 20Sydney

Partnership Opportunities: Pip Curtis | pcurtis@theiegroup.com | +1415 992 5349 Attendee Invitation: Sean Foreman | sforeman@theiegroup.com | +1415 692 5514

Big Data 2013 CALENDAR

Women

Finance

CXO Healthcare

Expected

Flagship

Government

High Tech Pharma

Hadoop

What you get...• Access to over 1000 hours of On-demand training on topics that are important to you, like S&OP, FP&A, Predictive

Analytics , Supply Chain, Strategic Planning, Inventory Optimisation, Integrated Business Planning and more• Access to our extensive training library. Whenever your team needs to benchmark or gain some key actionable ideas,

they just watch a quick video.• Monthly newsletters with industry insights and important news - vital for up-to-date info and methodology.

Affordable. Cutting Edge. Convenient. Invest in innovative business education that will help you benchmark and validate current and future initiatives that can be leveraged to optimise business results and effective decision making. IE. membership content spans numerous industry sectors and includes presentations from many of the world’s leading companies.

Membership Exclusive Content for Finance, Operations & Business Analytics.

What is the IE. Network?IE. is the premier forum for Finance, Operations Planning & Business Analytics education. Gain insight and optimize results with un-biased actionable business education available on-demand and delivered by your peers. Stay on the cutting edge of the latest trends within S&OP, FP&A & Business Analytics, all without having to leave your desk.

Learn from leading companies including:

Sign UpNow

click here

14

F TI L